Considerable effort has been made to override the T315I mutation ( Table 1). The ATP-noncompetitive Abl TKI, ON012380, was the first agent that was able to inhibit both wild-type and all imatinib ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

Key findings include: A 50% cumulative major molecular response (MMR) rate in non-T315I patients Reductions in BCR::ABL1 transcripts in 88% of MR1+ patients Significant responses observed post ...

Key findings include: A 50% cumulative major molecular response (MMR) rate in non-T315I patients Reductions in BCR::ABL1 transcripts in 88% of MR1+ patients Significant responses observed ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

Ascentage Pharma’s olverembatinib gets China NMPA’s BTD to treat Philadelphia chromosome-positive acute lymphoblastic leukemia: Rockville Friday, March 7, 2025, 11:00 Hrs [IST ...

Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation. Receive News & Ratings for Ascentage Pharma Group International Daily - Enter ...

To date, olverembatinib has been approved in China for the treatment of adult patients with TKI-resistant CML-CP or accelerated-phase CML (CML-AP) harboring the T315I mutation and adult patients ...

previously treated with two or more tyrosine kinase inhibitors (TKIs), as well as patients harbouring the T315I mutation. Novartis picked up a breakthrough designation for the drug in February on ...